ReviewHepatology international2024
Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease.
Review in Hepatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Environmental Endocrine-Disrupting Chemicals and Metabolic Dysfunction-Associated Steatotic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Circulating Fibroblast Growth Factor-21 in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Current obesity reports · 2025Pooled it
- Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Dihydroflavonoids outperform their flavonoid counterparts in lipid-lowering efficacy based on pairwise analyses.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ultra-rapid progression of MAFLD to cirrhosis and post-transplant steatosis in a patient with a polygenic risk profile.MedScience · 2026Article
- Machine Learning-Based Comparative Analysis of Blood Cell-Derived Inflammatory Indices for Predicting MAFLD and Liver Fibrosis: Evidence From NHANES 2017-2020.Journal of clinical laboratory analysis · 2026Article
- [Mesenchymal stem cell-derived exosomes: a new hope for metabolic-associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- The Value of Five Novel Anthropometric Indicators in Evaluating MASLD and Liver Fibrosis in MASLD: A Cross-Sectional Study.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Mesenchymal stem cells and extracellular vesicles for MAFLD: from biological mechanisms to translational prospects.Stem cell research & therapy · 2026Review
- Mendelian Randomization Analysis of Systemic Iron Status and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2026Article
- ZFP36 Alleviates MASLD Through Facilitating TEAD4 mRNA Degradation After Sleeve Gastrectomy.International journal of molecular sciences · 2026Article
- A bio-fortified whole tomato food supplement as potential dietary tool for the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Journal of translational medicine · 2026Article
- Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study.Scientific reports · 2026Article
- Association between depression and metabolic dysfunction-associated steatotic liver disease: a cross-sectional analysis from the paracelsus 10,000 Study.Hepatology international · 2026Article
- Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities.International journal of molecular sciences · 2026Article
- Efficacy and safety of lower-carbohydrate dietary patterns for metabolic associated fatty liver disease: evidence from randomized controlled trials with grade analysis.Nutrition & metabolism · 2026Article
- Hepatogenomics of MAFLD in Asian Population: Genetic Polymorphisms and Pathway-Based Insights.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Association between oral microbiome alpha and beta diversity and MASLD risk: a large-scale, population-based retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Body-composition phenotype axes provide additional explanatory information for cardiorespiratory fitness and liver-related metabolic risk within BMI strata.Frontiers in nutrition · 2026Article
- The correlation between the trajectory of plasma atherosclerosis-inducing index in the examination population and the risk of developing metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common chronic liver illness worldwide is metabolic dysfunction linked to fatty liver disease (MAFLD), which is poorly understood by doctors and patients. Many people with this disease develop steatohepatitis, cirrhosis and its consequences, as well as extrahepatic manifestations; these conditions are particularly common if they are linked to diabetes mellitus or obesity. A breakthrough with numerous benefits is the switch from NAFLD to MAFLD in terms of terminology and methodology. The diagnosis of MAFLD is based on affirmative criteria; unlike NAFLD, it is no longer based on exclusion. The diagnosis of MAFLD and the evaluation of steatosis and fibrosis is achieved using liver biopsy and non-invasive laboratory or radiographic techniques. We briefly address the most recent developments in MAFLD epidemiology and diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.